Market Cap : 1.03 B | Enterprise Value : 967.1 M | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Non-Recurring Items are the incomes received or expenses incurred by the business that are not from regular operations. Myovant Sciences's non-recurring items for the three months ended in Mar. 2022 was $0.0 Mil. Its non-recurring items for the trailing twelve months (TTM) ended in Mar. 2022 was $0.0 Mil.
As of today (2022-05-29), Myovant Sciences's share price is $10.84. Myovant Sciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 was $-2.21. Therefore, Myovant Sciences's PE Ratio without NRI ratio for today is At Loss.
The historical data trend for Myovant Sciences's Non Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Non-Recurring Items are the incomes received or expenses incurred by the business that are not from regular operations. Examples of NRI include gains (losses) from plant shutdown, lease-breaking fees, lawsuit, write-offs, write-downs, restructuring costs or sales of an investment, discontinued operations etc.
NRI can impact a company's reported income drastically.
Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuruFocus lists a PE Ratio without NRI, which is the price/earnings before NRI. We believe it more accurately reflects the valuation of the company.
Myovant Sciences's PE Ratio without NRI Ratio for today is calculated as
PE Ratio without NRI | = | Share Price | / | EPS without NRI |
= | 10.84 | / | -2.21 | |
= | At Loss |
Myovant Sciences's Share Price of today is $10.84.
Myovant Sciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.21.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Myovant Sciences's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Potter Myrtle S | director | 10 FINDERNE AVE BRIDGEWATER NJ 08807 |
Guinan Mark | director | C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
Arjona Ferreira Juan Camilo | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Curran Terrie | director | C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Gulfo Adele M. | director | ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
Sebelius Kathleen | director | C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025 |
Lang Matthew | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 60 WALL STREET NEW YORK NY 10005 |
Seely Lynn | director, officer: Principal Executive Officer | 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107 |
Sablich Kim | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Nomura Hiroshi | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 |
Torti Frank | director | 2855 SAND HILL ROAD MENLO PARK CA 94025 |
Other Sources
By Seekingalpha 2021-06-02
By Seekingalpha 2020-12-22
By Seekingalpha 2021-05-24
By Zacks 2021-07-01
By Zacks 2020-12-16
By Zacks 2021-02-11
By Zacks 2021-10-26
By Seekingalpha 2021-01-19
By Zacks 2021-04-13
By Zacks 2022-01-26
By Zacks 2021-05-11
By Fool 2021-07-28